# US Cell Viability Assays Market > US Cell Viability Assays Market Research Report: Size, Share, Trend Analysis By Product (Consumables, Instruments), By Cell Type (Human cells, Microbial cells, Animal cells) and By Applications (Stem cell research) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.5% - **2024:** $ 625.84 Million - **2025:** $ 679.04 Million - **2035:** $ 1,535.6 Million - **Key Players:** Thermo Fisher Scientific (US), Merck KGaA (DE), BD (US), Promega Corporation (US), Bio-Rad Laboratories (US), Abcam plc (GB), PerkinElmer (US), Roche Holding AG (CH) **Report ID:** MRFR/LS/17108-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-cell-viability-assays-market-18636 --- ## Market Summary ## **US Cell Viability Assays Market Overview** As per MRFR analysis, the US Cell Viability Assays Market Size was estimated at 330.32 (USD Million) in 2023. The US Cell Viability Assays Market Industry is expected to grow from 400(USD Million) in 2024 to 1,000 (USD Million) by 2035. The US Cell Viability Assays Market CAGR (growth rate) is expected to be around 8.687% during the forecast period (2025 - 2035). ### **Key US Cell Viability Assays Market Trends Highlighted** The US Cell Viability Assays Market is experiencing notable trends driven by the increasing prevalence of chronic diseases and the growing demand for advanced healthcare solutions. The shift towards personalized medicine and the rising focus on drug discovery and development are significant market drivers. Regulatory agencies in the US, such as the FDA, emphasize the importance of cell viability assays in preclinical trials and drug testing, further enhancing their adoption among pharmaceutical and biotech companies. The integration of automation and high-throughput screening technologies in laboratories is also gaining traction, improving efficiency and accuracy in assessing cell viability. Opportunities to be explored in the US market include the expansion of research activities in academia, coupled with increased funding from government bodies for biomedical research. This presents a chance for manufacturers to develop innovative assay technologies that cater to specific research needs. Additionally, the rise of contract research organizations (CROs) in the US, which provide outsourced research services, creates avenues for partnerships and collaborations that could lead to the advancement of cell viability assays. In recent times, there has been a notable trend towards the incorporation of advanced technologies such as artificial intelligence and machine learning in analyzing cell viability data. These technologies can enhance data interpretation and streamline workflow in research settings, providing a competitive edge to organizations that adopt them. Furthermore, the growing interest in regenerative medicine and cell therapy has spurred demand for reliable cell viability assays in clinical and research applications across the US, shaping a dynamic landscape for market growth. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **US Cell Viability Assays Market Drivers** #### **Rising Incidence of Cancer Cases in the United States** The increasing incidence of cancer cases in the United States is a major driver for the growth of the US [Cell Viability Assays](../../../reports/cell-viability-assays-market-6391) Market Industry. According to the American Cancer Society, an estimated 1.9 million new cancer cases are expected to be diagnosed in 2021. The need for effective cancer research and treatment continues to rise, boosting the demand for cell viability assays that are crucial in understanding the effectiveness of various cancer therapies. For instance, organizations such as the National Cancer Institute are actively involved in funding and conducting Research and Development (R&D) in cancer treatments, significantly increasing the usage of cell viability assays in clinical settings. As the US population ages, this trend is expected to continue, leading to a projected increase of about 27% in cancer cases over the next decade, which will further necessitate the utilization of these assays in oncological research and treatment. #### **Technological Advancements in Cell Viability Assays** Technological advancements in cell viability assays are significantly enhancing their accuracy and usability. Innovations such as automated systems and high-throughput screening methods have streamlined data collection, providing detailed insights into cell health and response to treatments. Companies like Thermo Fisher Scientific and Promega Corporation are at the forefront of these advancements, introducing new products that simplify cell viability assessment. The increased accuracy in assay results fosters confidence among researchers and clinicians, propelling the uptake of these assays across laboratories in the United States. As technology continues to evolve, it is expected to boost the US Cell Viability Assays Market Industry substantially. #### **Growing Research Funding from Public and Private Sectors** The growth of research funding from both public and private sectors is fueling the US Cell Viability Assays Market Industry. Federal bodies like the National Institutes of Health and various foundations are investing significantly in biomedical research, aiming to uncover new treatments for diseases. For example, NIH funding for cancer research has seen a steady increase, with budgets reaching over $6 billion for cancer-related studies. This financial support translates to a higher demand for cell viability assays in both academic and clinical research settings. Consequently, reliable and efficient assays will play a vital role in facilitating groundbreaking research, contributing to market growth. ### **US Cell Viability Assays Market Segment Insights** #### **Cell Viability Assays Market Product Insights** The US Cell Viability Assays Market is experiencing steady growth, primarily driven by advancements in biotechnology and a significant focus on Research and Development activities. The Product segment of this market includes various critical components such as consumables and instruments. Consumables play a key role in laboratory assays, as they consist of reagents, media, and various ancillary items essential for conducting experiments. The substantial investment in the healthcare sector within the US, along with increasing incidence rates of chronic diseases, has bolstered the demand for consumables, enhancing their importance within the Cell Viability Assays Market. Instruments represent another critical facet of the Product segment, encompassing equipment and devices utilized to perform cell viability tests. These instruments are fundamental for obtaining accurate and reliable data, which is vital for assessing cell health and response to treatments. The continuous innovation in instrument technology, such as the incorporation of automation and advanced imaging systems, has significantly improved assay performance and throughput, making these tools indispensable in laboratories across the nation. Additionally, the increasing adoption of cell-based assays in drug discovery and development processes within the US has further solidified the significance of both consumables and instruments in facilitating high-quality Research and Development. The combination of rising patient populations, growing investments in oncology research, and the need for precise testing methodologies are driving market trends in the US Cell Viability Assays Market. This landscape offers ample opportunities for growth, not just for consumables and instruments but also for new product innovations that enhance assay capabilities. Key challenges, such as rising costs associated with high-quality consumables and the need for sophisticated instruments, could impact market growth; however, the overall outlook remains positive as researchers continue to seek more efficient and effective solutions for cell viability assessment. This robust demand, coupled with the ongoing evolution of technologies and methodologies, underscores the critical nature of the Product segment within the broader US Cell Viability Assays Market landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review #### **Cell Viability Assays Market Cell Type Insights** The US Cell Viability Assays Market is significantly influenced by the Cell Type segment, encompassing categories such as Human, Microbial, and Animal cells, each characterized by unique applications and research significance. Human cells are crucial for drug development and disease research, making them pivotal for laboratory studies that require specific responses to therapeutic candidates. Microbial cells play a vital role in the biotechnology industry, particularly in antibiotic testing and environmental monitoring, thereby driving innovation and research efforts in these areas. Meanwhile, Animal cells are extensively utilized in toxicity screenings and cancer research, reflecting their importance in translational research fields. The interplay between these cell types not only enhances the understanding of biological processes but also supports various applications ranging from basic research to advanced drug discovery. Market growth in this domain is propelled by increasing adoption of cell-based assays in Research and Development, alongside a rise in chronic diseases in the US, necessitating effective therapeutic interventions tailored to different cell types. This dynamic emphasizes the need for advancements in assay technologies to meet the demands of diverse research scenarios, thus reinforcing the importance of the Cell Type segment within the broader US Cell Viability Assays Market landscape. #### **Cell Viability Assays Market Application Insights** The Application segment of the US Cell Viability Assays Market plays a critical role in various biological and medical research areas. Among these, Stem Cell Research stands as a significant focus, largely driven by the increasing need for advanced therapeutic options and regenerative medicine solutions. The U.S. government's support for stem cell studies, including funding initiatives and policies promoting research, contributes to the growing interest and investments in this field. This segment is essential for understanding cellular processes, drug efficacy, and toxicity, which ultimately drives innovations in treatment methods. Furthermore, the need for effective cell-based assays that provide accurate viability results underlines the importance of this segment. As researchers continue to delve deeper into the complexities of stem cells, the demand for reliable cell viability assays will likely expand, emphasizing the vitality of this segment within the overall market landscape. The contributions of Stem Cell Research extend far beyond basic science, impacting therapeutic applications and enhancing our understanding of various diseases. ### **US Cell Viability Assays Market Key Players and Competitive Insights** The competitive insights of the US Cell Viability Assays Market reflect a dynamic landscape characterized by rapid technological advancements, innovative product developments, and a growing focus on research and development for applications in drug discovery, cancer research, and other areas of life sciences. This market comprises a variety of players ranging from established leaders to emerging biotech firms, each competing through differentiation strategies including price, product features, and customer service. The demand for high-throughput screening methods coupled with an increasing emphasis on personalized medicine has further intensified competition, leading to strategic partnerships, collaborations, and acquisitions among key market players aiming to enhance their product offerings and market reach. Promega Corporation stands out in the US Cell Viability Assays Market due to its robust portfolio of products designed for cell health analysis, including assays for apoptosis, cytotoxicity, and proliferation. The company's strengths lie in its commitment to innovation and quality, which has positioned Promega as a trusted partner for researchers in both academic and commercial sectors. With a strong distribution network, Promega effectively reaches a wide range of customers across the United States, ensuring that its products are readily available to laboratories and research facilities. The company’s consistent focus on user-friendly solutions and comprehensive technical support further enhances its competitive edge, allowing it to maintain a leading position in the market. BioRad Laboratories also plays a significant role in the US Cell Viability Assays Market, leveraging its extensive experience in life science and clinical diagnostics. The company offers a variety of assays used to measure cell viability, including popular products that cater to specific applications within research and pharmaceutical development. BioRad's strengths include its innovative technologies and deep commitment to quality, which resonate well with the needs of its customers. The company is recognized for its strategic initiatives, including mergers and acquisitions that have allowed it to expand its product line and market presence effectively. By consistently investing in R&D and maintaining a customer-centric approach, BioRad Laboratories strengthens its foothold in the US market while addressing the evolving needs of researchers and institutions focused on cellular assays. #### **Key Companies in the US Cell Viability Assays Market Include** ### **US Cell Viability Assays Market Industry Developments** Recent developments in the US Cell Viability Assays Market reveal a notable focus on enhancing product offerings, particularly from companies like Promega Corporation, BioRad Laboratories, and Thermo Fisher Scientific. The market has seen an increased demand for innovative cell viability assays due to a growing emphasis on drug development and personalized medicine, especially during the COVID-19 pandemic, which has significantly accelerated scientific research and testing. In terms of acquisitions, in February 2023, BD announced the acquisition of cell analysis technologies to bolster their portfolio in the cell viability assay market. Additionally, Merck KGaA's acquisition of MilliporeSigma has strengthened their position in providing advanced assay solutions. Recent financial reports indicate a growth trajectory for companies such as Roche and PerkinElmer, attributed to the rising investment in Biotechnology and Pharmaceutical sectors in the US, which has led to heightened demand for reliable cell viability testing methods. Over the past few years, such trends have significantly shaped the competitive landscape of the US market, leading to increased collaborations among industry players and academic institutions focused on developing robust assay technologies. ### **US Cell Viability Assays Market Segmentation Insights** #### **Cell Viability Assays Market Product Outlook** #### **Cell Viability Assays Market Cell Type Outlook** #### **Cell Viability Assays Market Application Outlook** ## Market Drivers ### Increased Research Funding The cell viability-assays market is experiencing growth due to increased funding for research initiatives in the US. Government and private sector investments in biomedical research have surged, with funding reaching approximately $45 billion in 2025. This influx of capital supports the development of advanced cell viability assays, which are essential for drug discovery and toxicology studies. As researchers seek to understand cellular responses to various compounds, the demand for reliable and efficient assays rises. Consequently, this trend is likely to bolster the cell viability-assays market, as more laboratories adopt these technologies to enhance their research capabilities. ### Expansion of Biotechnology Sector The biotechnology sector in the US is witnessing rapid expansion. This expansion positively influences the cell viability assays market. With the biotechnology industry projected to grow at a CAGR of 7.4% from 2025 to 2030, the demand for innovative cell viability assays is likely to increase. Biotech companies require these assays for various applications, including drug development, genetic research, and regenerative medicine. As the sector continues to evolve, the cell viability-assays market is expected to benefit from the growing need for advanced testing methods that can accurately assess cell health and viability. ### Advancements in Assay Technologies Technological advancements in assay methodologies are significantly shaping the cell viability-assays market. Innovations such as high-throughput screening and automated systems are enhancing the efficiency and accuracy of cell viability testing. In 2025, The market for high-throughput screening technologies is expected to reach $3 billion in the US. This indicates a strong trend towards automation in laboratory settings. These advancements not only improve the reliability of results but also reduce the time and resources required for testing. As laboratories adopt these cutting-edge technologies, the cell viability-assays market is poised for substantial growth. ### Rising Incidence of Chronic Diseases The increasing prevalence of chronic diseases in the US drives the demand for cell viability assays. As conditions such as cancer, diabetes, and cardiovascular diseases become more common, there is a heightened need for effective therapeutic interventions. The cell viability-assays market plays a crucial role in the development of new treatments, as these assays are essential for evaluating the efficacy and safety of potential drugs. With chronic diseases affecting millions of Americans, the market for cell viability assays is likely to see sustained growth as researchers and pharmaceutical companies strive to address these health challenges. ### Growing Focus on Personalized Medicine The shift towards personalized medicine is significantly impacting the cell viability-assays market. As healthcare providers increasingly tailor treatments to individual patient profiles, the need for precise and reliable assays becomes paramount. In 2025, the personalized medicine market is projected to reach $2 trillion in the US, driving demand for cell viability assays that can evaluate patient-specific responses to therapies. This trend suggests that the cell viability-assays market will expand as pharmaceutical companies and research institutions invest in developing assays that cater to personalized treatment approaches, thereby enhancing patient outcomes. ## Future Outlook The [Cell Viability Assays Market](https://www.marketresearchfuture.com/reports/cell-viability-assays-market-6391) is projected to grow at an 8.5% CAGR from 2025 to 2035, driven by advancements in biotechnology and increasing demand for drug development. **New opportunities:** - Development of high-throughput screening technologies for rapid testing. Integration of AI-driven analytics for enhanced data interpretation. Expansion of product lines to include novel assay kits for specific cell types. By 2035, the market is expected to achieve substantial growth, reflecting evolving research needs and technological advancements. ## Segment Insights ### By Cell Type: Human cells (Largest) vs. Microbial cells (Fastest-Growing) The cell type segment of the US cell viability-assays market shows a clear distribution of market share among human, microbial, and animal cells. Human cells dominate this segment, driven by extensive research in biotechnology and drug discovery, which increasingly requires accurate cell viability assessments. On the other hand, microbial cells, although smaller in share, are gaining ground swiftly due to a surge in studies related to microbial interactions and antibiotic resistance, indicating their rising importance. Growth trends within this segment reflect an increasing trend towards precision medicine and personalized therapies, particularly for human cells which are essential in clinical testing. The rise of microbial cells as the fastest-growing segment is attributed to heightened research into environmental sustainability and microbial efficacy. This growth is fueled by innovations in assay technologies and a growing focus on developing bioproducts that rely on microbial viability testing. Human cells (Dominant) vs. Animal cells (Emerging) Human cells are the dominant force within the cell type segment, primarily due to their critical role in preclinical testing and therapeutic applications, contributing to the overall growth of the US cell viability-assays market. The focus on human cell assays is bolstered by the shift towards personalized medicine and advanced cellular therapies. In contrast, animal cells, while emerging, are increasingly being recognized for their relevance in translational research and toxicity testing. The demand for animal cell assays is being driven by regulatory requirements and the need for more accurate models that reflect human physiology, making this segment critical for bridging laboratory research to clinical applications. ### By Application: Stem Cell Research (Largest) vs. Cancer Research (Fastest-Growing) The application segment of the US cell viability assays market demonstrates a diverse distribution. Stem cell research occupies the largest share due to its extensive utilization in regenerative medicine and developmental biology. In this scope, the demand for accurate and reliable assays is crucial for advancements in stem cell therapy, which contributes significantly to its market dominance. In contrast, cancer research is rapidly emerging as the fastest-growing area, spurred by increasing investments in oncology and a heightened focus on personalized medicine. This sector's growth is driven by advancements in technology that facilitate high-throughput screening and real-time monitoring of cell health, making cancer research assays vital in developing targeted treatments and improving patient outcomes. Application: Stem Cell Research (Dominant) vs. Cancer Research (Emerging) Stem cell research is recognized as the dominant application in the US cell viability-assays market, largely due to its critical role in investigations pertaining to cellular regeneration and disease modeling. This segment is characterized by a robust demand for assays that can accurately measure cell viability and function, which are fundamental in both therapeutic development and basic research. Conversely, cancer research, as an emerging segment, is experiencing rapid adoption of innovative assays designed for specific tumor types, reflecting a shift toward precision medicine. This evolution is marked by the adoption of advanced cell viability techniques that promise greater specificity and reliability, thereby transforming how cancer therapies are developed and evaluated. ### By Product: Instruments (Largest) vs. Consumables (Fastest-Growing) In the US cell viability assays market, instruments dominate the product segment with a significant market share. This category has established itself as a critical component within laboratories and research institutions due to its essential role in cell analysis and diagnostics. Consumables, while trailing in overall share, represent an increasingly important aspect of the market, benefiting from the rising adoption of assays in various applications. The growth trends indicate a robust upward trajectory for Consumables, which are gaining traction as researchers seek more efficient and cost-effective solutions for cell viability testing. Factors such as technological advancements and increasing research activities are driving this growth. Furthermore, the push for more comprehensive assay solutions is anticipated to stimulate demand for both Instruments and Consumables in the coming years. Instruments: Dominant vs. Consumables: Emerging Instruments have solidified their position in the US cell viability-assays market as the dominant segment, characterized by high reliability and precision in cellular analysis. These tools are essential for various laboratory applications, adhering to rigorous standards that ensure consistent results. On the other hand, Consumables are rapidly emerging, driven by increasing laboratory throughput and demand for ready-to-use solutions. These include reagents and plates designed for specific assays, making them more favorable in research settings. The transition towards more innovative formulations and user-friendly designs in Consumables is expected to attract researchers, thereby enhancing their market presence. This dynamic showcases the crucial interplay between established technologies and evolving user requirements. ## Competitive Benchmarking The cell viability-assays market is characterized by a dynamic competitive landscape, driven by increasing demand for advanced research tools in drug discovery, cancer research, and toxicology studies. Key players such as Thermo Fisher Scientific (US), Merck KGaA (DE), and BD (US) are strategically positioned to leverage their extensive product portfolios and innovative capabilities. Thermo Fisher Scientific (US) focuses on enhancing its assay technologies through continuous innovation, while Merck KGaA (DE) emphasizes strategic partnerships to expand its market reach. BD (US) is actively pursuing digital transformation initiatives to improve operational efficiency and customer engagement, collectively shaping a competitive environment that prioritizes innovation and customer-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The market structure appears moderately fragmented, with several key players exerting considerable influence. This fragmentation allows for niche players to emerge, yet the collective strength of major companies like Promega Corporation (US) and Bio-Rad Laboratories (US) ensures a competitive balance that drives innovation and quality across the sector. In October Promega Corporation (US) announced the launch of a new line of cell viability assays designed to improve accuracy in high-throughput screening applications. This strategic move is likely to enhance Promega's competitive edge by addressing the growing need for precision in drug discovery processes, thereby attracting a broader customer base. The introduction of these advanced assays may also signify a shift towards more specialized products that cater to specific research needs. In September Bio-Rad Laboratories (US) expanded its product offerings by acquiring a small biotech firm specializing in cell-based assays. This acquisition is indicative of Bio-Rad's strategy to bolster its capabilities in the cell viability space, potentially allowing for the integration of novel technologies into its existing portfolio. Such strategic actions may enhance Bio-Rad's market position by providing researchers with more comprehensive solutions for cell analysis. In August Merck KGaA (DE) entered into a collaboration with a leading academic institution to develop next-generation cell viability assays utilizing AI-driven analytics. This partnership underscores Merck's commitment to innovation and positions the company at the forefront of technological advancements in the field. By integrating AI into assay development, Merck KGaA (DE) may significantly improve the efficiency and accuracy of cell viability assessments, thereby setting new industry standards. As of November current trends in the cell viability-assays market include a pronounced focus on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise for enhanced innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a greater emphasis on technological innovation, reliability in supply chains, and the development of sustainable practices. This transition may redefine market dynamics, compelling companies to innovate continuously to maintain their competitive edge. ## Recent News & Developments Recent developments in the US Cell Viability Assays Market reveal a notable focus on enhancing product offerings, particularly from companies like Promega Corporation, BioRad Laboratories, and Thermo Fisher Scientific. The market has seen an increased demand for innovative cell viability assays due to a growing emphasis on drug development and personalized medicine, especially during the COVID-19 pandemic, which has significantly accelerated scientific research and testing. In terms of acquisitions, in February 2023, BD announced the acquisition of cell analysis technologies to bolster their portfolio in the cell viability assay market. Additionally, Merck KGaA's acquisition of MilliporeSigma has strengthened their position in providing advanced assay solutions. Recent financial reports indicate a growth trajectory for companies such as Roche and PerkinElmer, attributed to the rising investment in Biotechnology and Pharmaceutical sectors in the US, which has led to heightened demand for reliable cell viability testing methods. Over the past few years, such trends have significantly shaped the competitive landscape of the US market, leading to increased collaborations among industry players and academic institutions focused on developing robust assay technologies. ## Report Scope | MARKET SIZE 2024 | 625.84(USD Million) | | --- | --- | | MARKET SIZE 2025 | 679.04(USD Million) | | MARKET SIZE 2035 | 1535.6(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.5% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Merck KGaA (DE), BD (US), Promega Corporation (US), Bio-Rad Laboratories (US), Abcam plc (GB), PerkinElmer (US), Roche Holding AG (CH) | | Segments Covered | Cell Type, Application, Product | | Key Market Opportunities | Advancements in high-throughput screening technologies enhance efficiency in the cell viability-assays market. | | Key Market Dynamics | Technological advancements drive innovation in cell viability-assays, enhancing accuracy and efficiency in research applications. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US cell viability-assays market?** A: The market valuation was $625.84 Million in 2024. **Q: What is the projected market size for the US cell viability-assays market by 2035?** A: The projected valuation for 2035 is $1535.6 Million. **Q: What is the expected CAGR for the US cell viability-assays market during the forecast period 2025 - 2035?** A: The expected CAGR is 8.5% during the forecast period. **Q: Which companies are considered key players in the US cell viability-assays market?** A: Key players include Thermo Fisher Scientific, Merck KGaA, BD, Promega Corporation, Bio-Rad Laboratories, Abcam plc, PerkinElmer, and Roche Holding AG. **Q: What segment had the highest valuation in the US cell viability-assays market in 2024?** A: The segment for stem cell research had the highest valuation at $625.84 Million. **Q: How do the valuations of different cell types compare in the US cell viability-assays market?** A: In 2024, human cells were valued at $250.0 Million, microbial cells at $200.0 Million, and animal cells at $175.84 Million. **Q: What are the product segments in the US cell viability-assays market and their valuations?** A: In 2024, instruments were valued at $250.0 Million and consumables at $375.84 Million. **Q: What is the growth outlook for the US cell viability-assays market?** A: The market is expected to grow significantly, reaching $1535.6 Million by 2035. **Q: What applications are driving growth in the US cell viability-assays market?** A: Stem cell research is a primary application driving growth, with a valuation of $625.84 Million in 2024. **Q: How does the market for microbial cells compare to that for animal cells in the US cell viability-assays market?** A: In 2024, the market for microbial cells was valued at $200.0 Million, while animal cells were valued at $175.84 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-cell-viability-assays-market-18636*